Market Overview

Bristol-Myers, Pfizer Announce Positive Phase 3 Trial Results for ELIQUIS

Share:
Related BMY
Bristol-Myers Squibb to Host Investor Teleconference to Discuss World Conference on Lung Cancer (WCLC) Highlights
U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Non-Squamous Non-Small Cell Lung Cancer Patients
Bristol-Myers' (BMY) Opdivo Gets Priority Review, Shares Up (Zacks)

Bristol-Myers
Squibb Company (NYSE: BMY) and Pfizer
Inc. (NYSE: PFE) today announced the results of the Phase 3
AMPLIFY-EXT trial, which evaluated treatment with ELIQUIS®
(apixaban) over a one-year period compared to placebo for the prevention
of recurrent venous thromboembolism (VTE) in 2,486 patients who had
already completed 6 to 12 months of anticoagulation treatment for VTE,
including deep vein thrombosis (DVT) or pulmonary embolism (PE). In the
trial, extended treatment with ELIQUIS 2.5 mg and 5 mg twice daily,
demonstrated superiority versus placebo in the reduction of the
composite endpoint of symptomatic, recurrent VTE and death from any
cause (11.6% in the placebo group, compared with 3.8% and 4.2% in the
ELIQUIS

See full press release

Posted-In: News Guidance Contracts Management

 

Related Articles (BMY + PFE)

Get Benzinga's Newsletters